Sacha Loiseau

ENSWEET develops a telemedicine platform enabling rehabilitation care to be carried out outside of health facilities. Our solution allows you to create new care paths, customized to each patient. Our mission: to make rehabilitation care accessible to all.

Sonio, a wholly-owned subsidiary of Samsung Medison Co., Ltd since 2024, is a highly customizable workflow and practice management solution powered by AI for automation, efficiency, and quality control. "Sonio AI-enhanced¹ software empowers ultrasound practitioners and readers. Sonio assists them in performing every prenatal examination to their highest quality standards, ensuring the completeness of each examination, streamlining their workflow, and in prenatal diagnosis. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI. ¹AI-enhancement is provided by FDA 510(k) cleared Sonio Detect product * Applicable to V1 only, Data enclosed at Sonio **See table 6 in the 510k summary: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240406.pdf

Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics.

GLEAMER offers a suite of AI solutions for radiology that encapsulate medical-grade expertise. Our company wants to support imaging readers to secure diagnoses for all patients at all times while improving comfort and workflow efficiency. Our team imagines and develops solutions booth at the level of an expert and is easy to integrate thanks to the joint work of a multi-disciplinary team encapsulating AI and radiologist experts. GLEAMER has already been integrated into more than 650 institutions in each part of the world. 🏅Alexander Margulis award - Scientific excellence for the BoneView clinical study 🏅 🏅 2023 Eurominnies awards - Best New Radiology Vendor🥇

Beyond Aero is building the first electric business aircraft powered by hydrogen propulsion, enabling six passengers to fly up to 800 NM (1,500 km), a range unattainable with battery-electric aircraft. Founded in December 2020, the company is redesigning the architecture of an aircraft around hydrogen-electric propulsion, focusing on fuel cell technology, gaseous hydrogen tank integration, and advanced cooling systems. With offices in Toulouse, Paris, and Los Angeles, the company boasts a team of over 80 highly qualified engineers from leading aerospace companies. Beyond Aero has secured over $50 million in funding, backed by investors such as Giant Ventures, Bpifrance, and prior supporters like Initialized Capital, Female Founders Fund, and 7 Percent Ventures. Beyond Aero also completed Y Combinator in 2022. The company has secured $1.1bn in Letters of Intent (LOIs), completed France’s first manned, fully hydrogen-electric flight, and acquired Universal Hydrogen Co.s assets, IP, and flight data. Beyond Aero is a member of the World Economic Forum’s First Movers Coalition and the Alliance for Zero Emission Aviation, underscoring its commitment to electrifying aviation with hydrogen propulsion.

Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The companys vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.

Rêvée et conçue par des soignantes, le Dr Elise Cabanes et Mariana Fernandes, infirmière anesthésite, Epoca est une jeune entreprise à mission qui combine le meilleur des technologies et de l’expertise médicale. Sa mission ? Permettre aux personnes âgées de vieillir à domicile, dans les meilleures conditions possibles tout en facilitant le quotidien des aidants et soignants. La solution développée par Epoca repose sur des objets connectés, sa plateforme de télésurveillance et sur le savoir-faire de son équipe médicale spécialisée en gériatrie disponible 7j/7, 24h24. Epoca accompagne aujourd’hui les acteurs du secteur médico-social pour assurer la continuité des soins auprès des personnes les plus fragiles de leur territoire ou établissement.

Streamline access, organization, and sharing of medical data to enhance the quality of care and clinical research.

Kiro is a fast-moving startup developing solutions for better patient care, powered by artificial intelligence. We aim at improving everyone’s health by supporting patients and doctors with understandable and relevant information. We believe that medical biology is at the heart of healthcare. It contributes greatly to the diagnosis, treatment and prevention of diseases. Our mission is to foster the interactions between laboratories, health professionals and patients, to go beyond results in patient care thanks to new technologies and artificial intelligence. Since its inception, Kiro has worked in close partnership with clinical biologists, doctors and medical experts to build together a new approach to medical biology that is more understandable, personalized and relevant for the sake of patients.

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the worlds first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

MDoloris Medical Systems is a young innovative start-up (ISO 9001 and ISO 13485 certified) created in June 2010 to leverage more than 23 years of academic research conducted at the University Hospital of Lille. Our mission is to provide clinicians with the means to efficiently, continuously and non-invasively asses patient pain and comfort. The goal is to personalize pain therapy, in order to avoid known adverse effects of over- or underdosage of those drugs. Our technology is ideal when patients are unable to communicate, such as when they are under general anesthesia or unconscious in intensive care units, and also in children and newborn infants, dementia and Alzheimer's patients, and more. ------------------------------------------------------------------------------------------------------------------------------------------- Valorisant plus de 23 années de recherche académique, réalisées au sein du CHRU de Lille, Mdoloris Medical Systems est une jeune start-up (certifiée ISO 9001 et ISO 13485) innovante crée en Juin 2010. Notre mission consiste à fournir aux cliniciens des technologies permettant une évaluation fiable, continue et non-invasive de la douleur et du confort de leurs patients. L'objectif consiste à personnaliser la thérapeutique antidouleur afin d’éviter les effets indésirables des sur ou sous dosages de ces drogues. Nos technologies prennent tout leur sens lorsque les patients sont dans l’incapacité d’exprimer le ressenti douloureux (sous anesthésie générale, patients inconscients en réanimation, mais également les enfants, les patients atteints de démence, Alzheimer etc…).

Streamline access, organization, and sharing of medical data to enhance the quality of care and clinical research.

Sensome is an innovative start-up developing a breakthrough sensing technology that can turn invasive medical devices into connected healthcare devices. Sensome is EN ISO 13485:2016 certified.

Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence.

ENSWEET develops a telemedicine platform enabling rehabilitation care to be carried out outside of health facilities. Our solution allows you to create new care paths, customized to each patient. Our mission: to make rehabilitation care accessible to all.

Sonio, a wholly-owned subsidiary of Samsung Medison Co., Ltd since 2024, is a highly customizable workflow and practice management solution powered by AI for automation, efficiency, and quality control. "Sonio AI-enhanced¹ software empowers ultrasound practitioners and readers. Sonio assists them in performing every prenatal examination to their highest quality standards, ensuring the completeness of each examination, streamlining their workflow, and in prenatal diagnosis. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI. ¹AI-enhancement is provided by FDA 510(k) cleared Sonio Detect product * Applicable to V1 only, Data enclosed at Sonio **See table 6 in the 510k summary: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240406.pdf

Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics.

GLEAMER offers a suite of AI solutions for radiology that encapsulate medical-grade expertise. Our company wants to support imaging readers to secure diagnoses for all patients at all times while improving comfort and workflow efficiency. Our team imagines and develops solutions booth at the level of an expert and is easy to integrate thanks to the joint work of a multi-disciplinary team encapsulating AI and radiologist experts. GLEAMER has already been integrated into more than 650 institutions in each part of the world. 🏅Alexander Margulis award - Scientific excellence for the BoneView clinical study 🏅 🏅 2023 Eurominnies awards - Best New Radiology Vendor🥇

Beyond Aero is building the first electric business aircraft powered by hydrogen propulsion, enabling six passengers to fly up to 800 NM (1,500 km), a range unattainable with battery-electric aircraft. Founded in December 2020, the company is redesigning the architecture of an aircraft around hydrogen-electric propulsion, focusing on fuel cell technology, gaseous hydrogen tank integration, and advanced cooling systems. With offices in Toulouse, Paris, and Los Angeles, the company boasts a team of over 80 highly qualified engineers from leading aerospace companies. Beyond Aero has secured over $50 million in funding, backed by investors such as Giant Ventures, Bpifrance, and prior supporters like Initialized Capital, Female Founders Fund, and 7 Percent Ventures. Beyond Aero also completed Y Combinator in 2022. The company has secured $1.1bn in Letters of Intent (LOIs), completed France’s first manned, fully hydrogen-electric flight, and acquired Universal Hydrogen Co.s assets, IP, and flight data. Beyond Aero is a member of the World Economic Forum’s First Movers Coalition and the Alliance for Zero Emission Aviation, underscoring its commitment to electrifying aviation with hydrogen propulsion.